Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study-Reference-Cited by-同舟云学术

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study

Published:2024-05-08 Issue:8 Volume:47 Page:759-769
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Shapiro Samantha B.^ORCID,Yin Hui,Yu Oriana H. Y.,Azoulay Laurent^ORCID

Funder

Canadian Institutes of Health Research

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40264-024-01434-4.pdf

Reference59 articles.

1. National Institute for Health and Care Excellence. Guideline: type 2 diabetes in adults: management. London: National Institute for Health And Care Excellence (Nice). Copyright National Institute For Health And Care Excellence; 2015.

2. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S98–110.

3. Moran G, Bakhai C, Song S, Agwu J. Type 2 diabetes: summary of updated nice guidance. BMJ Br Med J. 2022. https://doi.org/10.1136/bmj.o775.

4. Bonora B, Avogaro A, Fadini G. Extraglycemic effects of Sglt2 inhibitors: a review of the evidence. Diabet Metab Syndr Obes. 2020;13:161–74.

5. Filippatos T, Panagiotopoulou T, Elisaf M. Adverse effects of Glp-1 receptor agonists. Rev Diabet Stud. 2014;11(3–4):202–30.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction of a 3-year risk prediction model for developing diabetes in patients with pre-diabetes;Frontiers in Endocrinology;2024-06-13

2. DPP-4 inhibitors increase risk of gall bladder and bile duct disease;Reactions Weekly;2024-05-18